To systematically review and meta-analyze available evidence from randomized placebo-controlled trials (RCTs) investigating the effects of pomegranate juice consumption and blood pressure (BP).
Design and method:
A comprehensive literature search in Medline and Scopus was carried out to identify eligible RCTs. A meta-analysis of eligible studies was performed using a random-effects model. Quality assessment, sensitivity analysisand publication bias evaluations were conducted using standard methods.
Quantitative data synthesis from 8 RCTs showed significant reductions in both systolic [weighed mean difference (WMD): −4.96 mmHg, 95% CI: −7.67 to −2.25, p < 0.001) and diastolic BP (WMD: −2.01 mmHg, 95% CI: −3.71 to −0.31, p = 0.021) after pomegranate juice consumption. Effects on SBP remained stable to sensitivity analyses. Pomegranate juice reduced SBP regardless of the duration (> 12 wks: WMD = −4.36 mmHg, 95% CI: −7.89 to −0.82, p = 0.016) and < 12 wks: WMD = −5.83 mmHg, 95% CI: −10.05 to −1.61, p = 0.007) and dose consumed (> 240 cc: WMD = −3.62 mmHg, 95% CI: −6.62 to −0.63, p = 0.018) and < 240 cc: WMD = −11.01 mmHg, 95% CI: −17.38 to −4.65, p = 0.001, pomegranate juice per day) whereas doses > 240 cc provided a borderline significant effect in reducing DBP.
The present meta-analysis suggests consistent benefits of pomegranate juice consumption on BP. This evidence suggests it may be prudent to include this fruit juice in a heart-healthy diet.